German drug pricing reform is causing Eli Lilly and Boehringer Ingelheim to withdraw from European markets.

The entities involved

• Eli Lilly and Company →

  American pharmaceutical company

  • ExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Mon 17:18
  • The FDA approved Olumiant for pediatric indications on September 1, 2026.Mon 05:59
• Boehringer Ingelheim →

  German pharmaceutical company

  • Sheila Denton was appointed as General Counsel & Corporate Secretary at Boehringer Ingelheim.Mon 15:03
  • Boehringer Ingelheim and Palatin Technologies reported $13.2 million in revenue from their Fiscal 2026 collaboration.Mon 13:31

Related events

• Eli Lilly and Kailera Therapeutics are competing in the obesity treatment market.Sep 15
• Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.Jun 7
• Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.Jun 18
• Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.Aug 5
• The FDA is ending compounding grace periods as competition intensifies and Lilly faces pipeline setbacks in the GLP-1 market.Jun 7